CureTelligence

Company Overview

Snapshot

Founded in September 2022 by Vadim Zelikman, CureTelligence operates with 1–10 employees. The company has raised $950,000 across one funding round. In July 2022, CureTelligence secured a grant from the BIRD Foundation.

Business overview

CureTelligence develops DoseBot, a robotic system designed to enhance medication safety by identifying, dispensing, and administering medication. The platform leverages AI algorithms and multispectral tools to prevent medication errors, providing valuable data analysis and improving efficiency for medical staff. CureTelligence operates within the Health Tech & Life Sciences sector, focusing on digital healthcare and medical devices, and serves markets in the United States, Israel, Europe, and Japan.

Company Intelligence Q&A

What is CureTelligence's primary product?

CureTelligence develops DoseBot, a robotic system that uses AI and multispectral tools for safe medication identification, dispensing, and administration, aiming to prevent medication errors.

When was CureTelligence founded?

CureTelligence was founded in September 2022.

Who is the founder of CureTelligence?

Vadim Zelikman is the Co-founder and CEO of CureTelligence.

What is the status of CureTelligence?

CureTelligence is Non Active and ceased to operate in December 2024.

What is CureTelligence's total disclosed funding?

CureTelligence has raised a total of $950,000 across one funding round.